ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Insys Therapeutics, Inc." (INSY) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Insys Therapeutics, Inc." (INSY)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: MDVN,PIP,MNOV,DMPI

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

"Insys Therapeutics, Inc."© quotemedia

Company Profile

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.